Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERASur: Total Ablative Therapy for Limited Metastatic Colorectal Cancer
NCT05673148Phase 2Recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Oct 2023
- Primary completion
- Jul 2028
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial in colorectal cancer (CRC) (2 arms), sponsored by Cancer and Leukemia Group B. Primary endpoint: Overall Survival at 5 years. Started Oct 2023; status: recruiting.
02
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05673148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05673148.